BioSpace News Archive

Successfully completed NORSE 2 enrollment in July 2020 NORSE 1 topline results to be reported in August 2020

 IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with the Division of Infectious Diseases, Department of Medicine at Columbia University, IsoPlexis’ Single-Cell Secretome immune profiling solutions will be used to study cellular drivers of durable and protective immune response to COVID-19.

- Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease (AD) has reached 500 patients toward the study’s previously announced en

Masimo PVi ® Receives FDA Clearance as an Indicator of Fluid Responsiveness on Mechanically Ventilated Patients

- Results presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting - Single-dose treatment with Solosec® resulted in a highly statistically significant response rate, or microbiological cure, in 92-95% of patients versus 1.5-1.7% in placebo - Lupin plans to submit a supplemental New Drug Application for Solosec® to the FDA for the treatment of trichomoniasis later this year

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19 th , 2020 to discuss the 2 nd quarter 2020 financial results and business update. The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to join the Teligent, Inc. call. This ca

Kaskela Law LLC announces that it is investigating Cellular Biomedicine Group, Inc. (“Cellular Biomedicine”) (Nasdaq: CBMG) on behalf of the company’s shareholders. On August 12, 2020 , Cellular Biomedicine announced that it had entered into a definitive agreement whereby each currently outstanding share of the company’s common

Healics is excited to announce it has become a 100% employee-owned ESOP company.

nc. Magazine revealed this week that Aspen Laser Systems has been selected for its Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in the United States

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 11:20 a.m. ET . Anthony Hayes , CEO of AIkido Pharma Inc. will be presenting to a live audience.